Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Sunday, June 30, 2019

Ubiome MEBO study and Bloodtype

MEBO-UBIOME stool DNA study update
Ubiome kindly gave MEBO many Explorer Stool DNA test kits to try and profile our community for this test.

Professor Irene Gabashvili, PhD., MEBO Scientific Director is conducting the MEBO - UBIOME community study on people with METABOLIC MALODOR, other MALODOR types, and PATM.
The full paper will be completed soon.

As it draws to a close Irene can look at the stats and show points of interest.

In Irene's recent AURAMETRIX blog post, Irene has focused on BLOODTYPE among the MEBO community and the world average.

Current MEBO-Ubiome Study participant totals :

Each participant was allowed to get 4 free Ubiome Stool Explorer test kits.
43 returned all samples and completed the questionaire.
8 returned 1 sample.
40+ got kits but didn't do the questionaire.

It's not too late to complete the trial (for those who already signed up).
It's too late for new participants to take part.

Prof Irene's provisional stats on Bloodtype among the MEBO group.

Quote from Irene on the results
The most common blood type in the world is O+ (~36.4%). About 4.3% have blood type O-. Blood types A+, B+ and AB+ are prevalent at approximately 28.3%, 20.6% and 5.1% respectively. Percentages for A-, B- and AB- are 3.5%, 1.4% and 0.5%.
These percentages may differ by country, but it appears that A- and B- blood types are less prevalent in MEBO population, while O and AB are more common.

Symptom-less diet was also different for different blood group types. Average Quality of Life score was 83, 92, 95 and 91 for O, A, B and AB groups, respectively (best for B, then A, worst for O), while MEBO symptoms were also least severe and most controllable for B- type, but worse for those with A antigens. The widest variation in MEBO symptoms was in the AB group.
Irene's full post on her AURAMETRIX blog can be seen here :  Aurametrix Blog Post

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization


Post a Comment